Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | SCN4A | P35499 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30944282 | 0.84 | CYP3A4 (0.69) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| SCHEMBL23719775 | 0.83 | RAB9A (0.63) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| SCHEMBL9484033 | 0.83 | RAB9A (0.76) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| SCHEMBL9722833 | 0.81 | CYP3A4 (0.65) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| SCHEMBL20568080 | 0.81 | RAB9A (0.84) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| Riluzole SCHEMBL29359189 | 0.81 | RAB9A (1.00) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| Riluzole SCHEMBL8913448 | 0.81 | RAB9A (1.00) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| Riluzole SCHEMBL78905 | 0.81 | RAB9A (1.00) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| Riluzole SCHEMBL5053829 | 0.81 | RAB9A (1.00) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 | |
| SCHEMBL9071102 | 0.81 | TDP1 (0.59) | RAB9ACYP3A4NPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3758697-B1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | CRESTONE INC (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118772080-A | Antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-10-15 | — | — | CN | claimed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | claimed |
| US-11655225-B2 | Antimycobacterial heterocyclic amides | CRESTONE, INC. (US) | 2023-05-23 | — | — | US | claimed |
| CN-112423746-A | Novel anti-mycobacterial heterocyclic amides | 克莱斯通公司 | 2021-02-26 | — | — | CN | claimed |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | CRESTONE, INC. | 2021-01-07 | — | — | US | claimed |
| EP-3758697-A1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | Crestone, Inc. (US) | 2021-01-06 | — | — | EP | claimed |
| EP-3758697-B1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | CRESTONE INC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118772080-A | Antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11655225-B2 | Antimycobacterial heterocyclic amides | CRESTONE, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-112423746-A | Novel anti-mycobacterial heterocyclic amides | 克莱斯通公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | CRESTONE, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| US-4675331-A | INSECTICIDE | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1987-06-23 | — | — | US | disclosed |
| EP-0198244-A2 | Benzoyl ureas | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-10-22 | — | — | EP | disclosed |
| EP-0196547-A1 | Benzamides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | RAB9A 333/4885CYP3A4 2815/4885NPC1 896/4885 |
| US-11655225-B2 | Antimycobacterial heterocyclic amides | AADAC, CPS1, NAT1 | RAB9A 1973/4885CYP3A4 650/4885NPC1 1093/4885 |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | AADAC, CPS1, ACAT1 | RAB9A 1886/4885CYP3A4 743/4885NPC1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.